Lantheus Holdings, Inc. (NASDAQ:LNTH) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Lantheus Holdings, Inc. (NASDAQ:LNTH) has a rating of ‘Buy’ or equivalent from almost 80% of the analysts covering the stock. With a median price target of $75, the stock has an upside potential of 18.48% from the current price.
On November 24, Matthew Taylor, an analyst at Jefferies, reiterated a Buy rating on Lantheus Holdings, Inc. (NASDAQ:LNTH), while keeping the price target at $105, which suggests an upside potential of 66%.
A and N photography/Shutterstock.com
Earlier on November 12, Leerink Partners trimmed its price target on Lantheus Holdings, Inc. (NASDAQ:LNTH) to $90 from $97, with an unchanged ‘Overweight’ rating. The analyst believes that 340B pricing pressures and competitive dynamics will influence the company’s Pylarify franchise, leading to a downgrade of the outlook.
When Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its third-quarter results on November 6, it delivered mixed financial performance. Although revenue surpassed consensus estimates by about 5%, the diluted EPS came at 2% below consensus expectations. The lower Pylarify revenues were attributed to “340B best price-driven price compression and competitive pressures from Ga-68 PSMA PET agents at large accounts.”
Lantheus Holdings, Inc. (NASDAQ:LNTH) is a Massachusetts-based company specializing in diagnostic and therapeutic products for the treatment of a diverse range of diseases. Incorporated in 1956, the company offers DEFINITY, TechneLite, Xenon-133, and Neurolite, among others.
While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
 is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Lantheus Holdings, Inc. (NASDAQ:LNTH) has a rating of ‘Buy’ or equivalent from almost 80% of the analysts covering the stock. With a median price target of $75, the stock has an upside potential of 18.48% from […]){kind=link}